Complex Regional Pain Syndrome (CRPS) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Complex Regional Pain Syndrome Market is Segmented By Disease Type (CRPS I, CRPS II, CRPS-NOS), Therapy Type (Drugs, Spinal Cord Stimulation, Surgical Sympathectomy, Others) and Geography.

Complex Regional Pain Syndrome Market Snapshot

Complex Regional Pain Syndrome Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 2.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global complex regional pain syndrome market studied was anticipated to grow with a CAGR of nearly 2.1% during the forecast period. CRPS is a condition of chronic pain that affects legs, arms, feet, and hands; which occurs after an injury. It is categorized into two types: CRPS-I and CRPS-II. Individuals who don’t have confirmed nerves injury are classified in CRPS-I and those who have confirmed nerve associated injury are classified in CRPS-II.

Rise in the number of patients suffering from complex regional pain syndrome (CRPS), chronic pain and failed back syndrome are the key factors boosting the market growth. According to the National Institute of Neurological Disorders and Stroke (NINDS), CRPS is commonly found in women and can occur in any age. In addition, 90 percent of cases triggered due to trauma and injury. Thus, an increasing number of patients suffering from chronic pain drive market growth.

Moreover, rising number of initiatives undertaken by nonprofit organizations, an increase in R&D funding by both private & public organizations and supportive government legislation are some of the crucial factors expected to drive the market in the coming few years. For instance, The International Research Foundation for RDS/ CRPS established an international research network which will help to educate medical professional and support research.

Rising number of potential clinical pipeline candidates is one of the key factors expected to propel the market growth. Moreover, upsurge in number of clinical trials to expand its target patient base with the existing drug portfolio is also amongst some of the drivers of this market. Growing R&D activities are expected to propel market growth. Some of the pipelined drugs are NKTR-181, Upadacitinib, Golodirsen and Tafamidis meglumine. However, lack of awareness about target disease in developing countries may restrain the growth of the market.

Scope of the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 202. For the purpose of this study, Mordor Intelligence has segmented the global complex regional pain syndrome market report on the basis of product, application, and region.

Report scope can be customized per your requirements. Click here.

Key Market Trends

CRPS I Dominates the Market and is Expected to Continue to Do the Same during the Forecast Period

  • CRPS I is expected to dominate the market through the forecast period. Individuals without a confirmed nerve injury are classified as having CRPS-I (previously known as reflex sympathetic dystrophy syndrome). This can be attributed to the rise in number of patients suffering from complex regional pain syndrome type 1. According to the Mayo Foundation for Medical Education and Research, about 90% of people with CRPS have type 1. Thus, the increasing number of patients suffering from chronic pain drive market growth.
  • Thus, the segment is witnessing a shift toward combination therapies that provide enhanced results to patients. Higher availability for treatment, positive results and reimbursement policies by key players for the target disease are supplementing the growth of the segment. Focus on developing new drugs to address the changing needs of the patients in the treatment poised to create a significant shift in prescription patterns.
Complex Regional Pain Syndrome Market

North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.

North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Heightened awareness of disease remittance therapies among patients, rising prevalence of CRPS, and high public and private healthcare spending are stimulating the growth of the region. Moreover, easy access to quality healthcare, favorable reimbursement policies, strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America.

The Asia Pacific is likely to post the fastest market throughout the forecast horizon. Growing adoption of urban lifestyle is leading to an expanding the base of patients in the region. This, coupled with increasing healthcare spending, is expected to propel the market in APAC. Favorable regulatory policies for drug approval are estimated to boost demand for the regional market over the forecast period.

Complex Regional Pain Syndrome Market

Competitive Landscape

Investment in R&D is one of the strategic measures to beat the competition. The key players in this market are Allergan, Boston Scientific Corporation, GlaxoSmithKline plc., ICU Medical, Johnson & Johnson and Medtronic.

The players operating in the market focus on introducing new products to address the changing need of the patients. For instance, Medtronic implantable neurostimulation system, which is designed to reduce the chronic pain of the limb or of the trunk. It is used for the treatment of failed back syndrome, post laminectomy pain, peripheral causalgia, epidural fibrosis, unsuccessful disk surgery, and CRPS.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Complex Regional Pain Syndrome

      2. 4.2.2 Increase in Number of Patients Suffering from Chronic Pain

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness about Target Disease in Developing Countries

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease Type

      1. 5.1.1 CRPS I

      2. 5.1.2 CRPS II

      3. 5.1.3 CRPS-NOS

    2. 5.2 By Therapy Type

      1. 5.2.1 Drugs

        1. 5.2.1.1 Analgesics

        2. 5.2.1.2 Antidepressants

        3. 5.2.1.3 Corticosteroids

      2. 5.2.2 Spinal Cord Stimulation

      3. 5.2.3 Surgical Sympathectomy

      4. 5.2.4 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Allergan

      2. 6.1.2 Boston Scientific Corporation

      3. 6.1.3 GlaxoSmithKline plc.

      4. 6.1.4 ICU Medical

      5. 6.1.5 Johnson & Johnson

      6. 6.1.6 Medtronic Plc

      7. 6.1.7 Viatris

      8. 6.1.8 Nevro Corp.

      9. 6.1.9 Purdue Pharma

      10. 6.1.10 Sanofi S.A

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Complex Regional Pain Syndrome (CRPS) Market market is studied from 2018 - 2026.

The Complex Regional Pain Syndrome (CRPS) Market is growing at a CAGR of 2.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Boston Scientific Corporation, Medtronic, GlaxoSmithKline plc., Johnson & Johnson , Viatris are the major companies operating in Complex Regional Pain Syndrome (CRPS) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!